In HIV-infected patients, when can trimethoprim‑sulfamethoxazole (Bactrim) prophylaxis for Pneumocystis jirovecii pneumonia (PCP) be discontinued?

Discontinuing Bactrim for PCP Prophylaxis in HIV Patients

Bactrim (TMP-SMX) for primary PCP prophylaxis should be discontinued when CD4+ count rises above 200 cells/µL for at least 3 consecutive months in response to antiretroviral therapy (ART). 1

Primary Prophylaxis Discontinuation Criteria

The evidence-based threshold for safely stopping prophylaxis requires both of the following:

• CD4+ count >200 cells/µL
• Sustained for ≥3 months on effective ART

This recommendation comes from multiple observational studies and randomized trials where the median CD4+ count at discontinuation was actually >300 cells/µL, and most patients had undetectable HIV viral loads. The median follow-up in these studies ranged from 6-16 months without PCP breakthrough cases. 1

Why This Threshold Works

Discontinuing prophylaxis at this point is safe because:

• The risk of PCP becomes negligible with immune reconstitution
• It reduces pill burden, drug toxicity, drug interactions, and cost
• It prevents selection of TMP-SMX-resistant organisms 1

Secondary Prophylaxis (After Prior PCP Episode)

For patients with a history of PCP, the discontinuation criteria are identical:

• CD4+ count >200 cells/µL for ≥3 months on ART
• This applies to chronic maintenance therapy (secondary prophylaxis) 1

The evidence supporting secondary prophylaxis discontinuation includes observational studies, randomized trials, and a combined analysis of eight European cohorts showing safety of this approach. 1

When to Restart Prophylaxis

Restart Bactrim immediately if CD4+ count drops below 200 cells/µL at any subsequent measurement. 1

Special Considerations

The 100-200 cells/µL Gray Zone

Recent research suggests that patients with CD4+ counts between 101-200 cells/µL and fully suppressed viral load may safely discontinue prophylaxis (incidence of PCP only 0.48 cases per 100 person-years). 2 However, this is not yet incorporated into official guidelines.

For CD4+ counts ≤100 cells/µL, continue prophylaxis regardless of viral suppression—inadequate data exist to support discontinuation at this lower threshold. 2

Common Pitfall: Premature Discontinuation

Do not stop prophylaxis based on a single CD4+ measurement >200 cells/µL. The 3-month sustained elevation requirement is critical—it ensures durable immune reconstitution rather than transient fluctuation. Most supporting studies had patients with CD4+ counts well above 200 cells/µL (median >300 cells/µL) at discontinuation, providing an additional safety margin. 1

Viral Load Consideration

While current guidelines don't require viral suppression for discontinuation decisions, the supporting evidence predominantly involved patients with suppressed HIV RNA levels. In clinical practice, confirm viral suppression when possible before discontinuing prophylaxis, especially if CD4+ count is closer to 200 cells/µL rather than 300+ cells/µL. 1, 2

Resource-Limited Settings

Where CD4+ monitoring is unavailable, total lymphocyte count (TLC) may serve as a surrogate—a sustained TLC ≥2000 cells/mm³ corresponds to CD4+ ≥200 cells/µL in approximately 85% of cases. 3 However, this is suboptimal compared to actual CD4+ measurement.

Algorithm Summary

1. Check CD4+ count while patient is on ART
2. If CD4+ >200 cells/µL: Recheck in 3 months
3. If still >200 cells/µL at 3 months: Discontinue Bactrim
4. Continue monitoring CD4+ counts regularly
5. If CD4+ drops <200 cells/µL: Restart Bactrim immediately